SYBX.OTC.PinkSynlogic, INC
10-K/A: Synlogic Files Amended 10-K to Include Omitted Executive and Governance Information
Sentiment:
10-K/A Filing
Synlogic files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and accounting fees.
Summary
- Synlogic, Inc. filed Amendment No. 1 to its Annual Report on Form 10-K/A for the year ended December 31, 2024.
- The amendment includes information intentionally omitted from Part III of the original filing, specifically Items 10, 11, 12, 13, and 14.
- These items cover Directors, Executive Officers and Corporate Governance, Executive Compensation, Security Ownership, Related Transactions, and Principal Accounting Fees and Services.
- The original filing was submitted on March 6, 2025.
- The amendment includes currently dated certifications pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
- The aggregate market value of common stock held by non-affiliates as of June 28, 2024, was $4.1 million, based on a closing price of $1.50 per share.
- As of March 31, 2025, there were 11,696,109 shares of common stock outstanding.
- The Board of Directors consists of four members: Peter Barrett, James Flynn, Edward Mathers, and Richard P. Shea.
- Mary Beth Dooley serves as the Principal Executive Officer and Principal Financial Officer.
- The company has adopted a Clawback Policy to recover excess incentive compensation in the event of an accounting restatement.
Sentiment
Score: 5
Explanation: The document is primarily factual, reporting on the filing of an amendment to a financial report. The sentiment is neutral as it mainly conveys information without expressing strong positive or negative views.
Positives
- The company has a Clawback Policy in place to recover excess incentive compensation.
- The company is committed to corporate governance, risk oversight, and ethics and compliance.
- The company provides ongoing learning and leadership training opportunities to employees.
- The company offers a competitive compensation and benefits package to its employees.
Negatives
- The company had to file an amendment to its annual report due to the intentional omission of key information.
- The company discontinued Synpheny-3, its pivotal study of labafenogene marselecobac (SYNB1934) as a potential treatment for PKU.
Risks
- The company's forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from expectations.
- The company faces risks related to research and development, clinical trials, regulatory approvals, collaborations, manufacturing, commercialization, and competition.
- The company's business could be adversely impacted by health epidemics or pandemics, such as COVID-19.
Future Outlook
The amendment contains forward-looking statements that involve risks and uncertainties, and actual results may differ materially from expectations.
Industry Context
The document does not provide specific details on how this announcement relates to broader industry trends or competitors.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Principal Executive Officer | Antoine Awad | Mary Beth Dooley | January 1, 2025 | Antoine Awad resigned. |
| Principal Financial Officer | N/A | Mary Beth Dooley | March 18, 2024 | Appointment of Mary Beth Dooley |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Clawback Policy | The Board adopted a Clawback Policy to recover excess incentive compensation in the event of an accounting restatement. | September 20, 2023 | Aims to ensure accountability and prevent unjust enrichment in case of financial misreporting. |
| Non-Employee Director Compensation Program | Amended & Restated Non-Employee Director Compensation Program adopted, providing equity compensation to non-employee directors. | April 26, 2025 | Provides equity compensation to non-employee directors, aligning their interests with those of the company. |
Stakeholder Impact
- The filing of the amendment ensures transparency and provides stakeholders with complete information about the company's financials and governance.
- The company's commitment to corporate governance and ethics aims to protect the interests of stakeholders.
- The company's investment in employees through training and benefits can improve employee satisfaction and productivity.
Key Dates
| Date | Description |
|---|---|
| March 2014 | Peter Barrett, Ph.D. served as the Chairman of the Private Synlogic board of directors. |
| May 15, 2017 | Agreement and Plan of Merger and Reorganization, dated as of May 15, 2017, by and among Mirna Therapeutics, Inc., Meerkat Merger Sub, Inc. and Synlogic, Inc. |
| August 28, 2017 | The Merger closed. |
| October 2018 | Aoife M. Brennan, MB, BCh, BAO, MMSc was appointed as President and Chief Executive Officer. |
| December 17, 2018 | Antoine Awad was hired as Head of Technical Operations. |
| January 1, 2019 | The company started to match employee contributions to the 401(k) plan. |
| July 2020 | Antoine Awad was appointed as Chief Operating Officer. |
| July 23, 2021 | Sales Agreement, dated as of July 23, 2021 by and between the registrant and Jefferies LLC |
| September 20, 2023 | Our Board adopted a Clawback Policy to comply with the new Clawback rules ad listing standards promulgated by the SEC and Nasdaq Stock Market, respectively. |
| November 2023 | Mary Beth Dooley was promoted as the Head of Finance. |
| December 2023 | The Amended and Restated Employment Agreement with Dr. Brennan was further amended. |
| January 2024 | The company granted options to named executive officers. |
| February 2024 | The Compensation Committee and the Board approved an annual increase in base salaries for certain employees effective as of January 1, 2024. |
| February 17, 2024 | We entered into a separation agreement with Dr. Brennan. |
| March 2024 | The Board appointed Mr. Awad as the Principal Executive Officer. |
| March 6, 2025 | Original Filing of the 10-K. |
| March 9, 2024 | Dr. Brennan's employment terminated. |
| March 18, 2024 | Mary Beth Dooley was appointed Principal Financial Officer. |
| March 19, 2024 | James Flynn was appointed to the Board. |
| April 26, 2025 | The Amended & Restated Non-Employee Director Compensation Program was adopted. |
| June 28, 2024 | The aggregate market value of common stock held by non-affiliates was $4.1 million. |
| December 4, 2024 | Synlogics annual meeting was held. |
| December 17, 2024 | We entered into a separation agreement with Antoine Awad. |
| December 19, 2024 | We entered into an employment agreement with Ms. Dooley. |
| December 31, 2024 | Mr. Awad's employment terminated. |
| January 1, 2025 | Mary Beth Dooley was appointed Principal Executive Officer and Principal Financial Officer. |
| February 20, 2025 | Michael Heffernan resigned from the Board. |
| March 31, 2025 | There were 11,696,109 shares of common stock outstanding. |
| April 30, 2025 | Filing date of this Amendment No. 1 to Annual Report on Form 10-K/A. |
Keywords
executive compensation, corporate governance, directors, security ownership, related transactions, accounting fees, Synlogic, 10-K/A
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.